Canada Gazette, Part I, Volume 157, Number 48: GOVERNMENT NOTICES
December 2, 2023
DEPARTMENT OF CITIZENSHIP AND IMMIGRATION
IMMIGRATION AND REFUGEE PROTECTION ACT
Ministerial instructions with respect to the processing of study permit applications
Notice is hereby given under subsection 87.3(6) of the Immigration and Refugee Protection Act (the Act) that the Minister of Citizenship and Immigration has established the following ministerial instructions that, in the opinion of the Minister, will best support the attainment of the immigration goals established by the Government of Canada.
These Instructions are consistent with the Act’s objectives, as set out in section 3. Specifically, in order to allow Canada to pursue the maximum social, cultural and economic benefits of immigration while maintaining the integrity of the Canadian immigration system, these instructions establish that an applicant must identify on their application a Designated Learning Institution that provides to the Department information regarding whether it has accepted a foreign national to undertake a program of study provided by that institution, as a condition that must be met before the processing of a study permit under subsection 216(1) of the Immigration and Refugee Protection Regulations (the Regulations). This will ensure that the regulatory requirement that students must have been accepted to a program of study at a Designated Learning Institution is assessed reliably, and that international student applications are processed in a timely, efficient and reliable way while deterring fraud.
Instructions are directed to officers who are charged with processing applications for study permits, by establishing conditions that must be met before the processing of an application.
Scope
These Instructions apply to applications for study permits made before entry to Canada submitted to the Department of Citizenship and Immigration on or after the coming into force of these Instructions.
Instructions
Definition
- 1 The following definition applies in these Instructions.
- Designated Learning Institution
- has the same meaning as in section 211.1 of the Regulations. (établissement d’enseignement désigné)
Verification of acceptance
2(1) Officers are instructed not to proceed with processing and to return applications for study permits made by foreign nationals before entry to Canada under section 213 of the Regulations if the Designated Learning Institution identified on the application has not, within 10 calendar days following receipt of the application, indicated whether the foreign national has been accepted to undertake a program of study by that institution.
Electronic applications
(2) For the purpose of subsection (1), officers are instructed not to proceed with processing and to return applications made by electronic means if the Designated Learning Institution has not indicated whether the foreign national has been accepted to undertake a program of study by that institution using the electronic system prescribed in section 3.
Extension
(3) The Minister of Citizenship and Immigration may, upon request from the Designated Learning Institution, grant a single extension of no more than 30 days to the period referred to in subsection (1) if the Minister determines that the Designated Learning Institution’s ability to indicate whether the foreign national has been accepted to undertake a program of study by that institution has been prevented or impeded by a
- (a) prolonged failure of power, communications or other infrastructure systems;
- (b) natural disaster;
- (c) public health emergency; or
- (d) labour dispute.
Electronic system
- 3 The Letter of Acceptance Verification Tool of the Department of Citizenship and Immigration is the electronic system that is to be used to provide the response from a Designated Learning Institution to indicate whether a foreign national who has submitted an application for a study permit under section 213 of the Regulations has been accepted to undertake a program of study by that institution for the purpose of subsection 2(2) of these Instructions.
Payment by applicant
- 4 A fee payable under section 300 of the Regulations in respect of a foreign national who makes an application for a study permit shall be refunded if the application has been returned unprocessed pursuant to section 2 of these Instructions.
Coming into effect
- 5 These instructions come into effect on December 1, 2023.
The Hon. Marc Miller, P.C., M.P.
Minister of Citizenship and Immigration
DEPARTMENT OF THE ENVIRONMENT
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Order 2023-66-11-02 Amending the Non-domestic Substances List
The Minister of the Environment makes the annexed Order 2023-66-11-02 Amending the Non-domestic Substances List under subsection 66(2)footnote a of the Canadian Environmental Protection Act, 1999 footnote b.
Gatineau, November 23, 2023
Steven Guilbeault
Minister of the Environment
Order 2023-66-11-02 Amending the Non-domestic Substances List
Amendment
| 19636-4 | Carbamic acid, N-[3-(trimethoxysilyl)propyl]-, alkanediyl ester |
|---|
Coming into Force
2 This Order comes into force on the day on which it is published in the Canada Gazette.
DEPARTMENT OF THE ENVIRONMENT
CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999
Order 2023-87-11-02 Amending the Non-domestic Substances List
Whereas, under subsection 87(5) of the Canadian Environmental Protection Act, 1999 footnote b, the Minister of the Environment has added the substance referred to in the annexed Order to the Domestic Substances List footnote c;
Therefore, the Minister of the Environment makes the annexed Order 2023-87-11-02 Amending the Non-domestic Substances List under subsection 87(5) of the Canadian Environmental Protection Act, 1999 footnote a.
Gatineau, November 23, 2023
Steven Guilbeault
Minister of the Environment
Order 2023-87-11-02 Amending the Non-domestic Substances List
Amendment
1 Part I of the Non-domestic Substances List footnote 1 is amended by deleting the following:
- 2041102-78-5
Coming into Force
2 This Order comes into force on the day on which Order 2023-87-11-01 Amending the Domestic Substances List comes into force.
DEPARTMENT OF HEALTH
DEPARTMENT OF HEALTH ACT
Notice of annual increase of Health Canada’s Drug Master Files and Certificate of Pharmaceutical Product fees
Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, updates the fees that are payable for the provision of Drug Master Files and Certificate of Pharmaceutical Product services by 2%.
The current fees and the fees updated as of April 1, 2024, are listed below.
Any inquiries or comments about the updated fees can be directed to Shannon Laforce, Acting Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 343‑572‑4094 (telephone) or cro-brc@hc-sc.gc.ca (email).
| Services | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|
| Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) | $98 | $100 |
| New Master Files (file registration) | $1,351 | $1,379 |
| Drug Master Files — letter of access | $192 | $196 |
| Drug Master Files — update | $587 | $599 |
DEPARTMENT OF HEALTH
FINANCIAL ADMINISTRATION ACT
Notice of annual adjustment of fees for dealer’s licences
Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the Fees in Respect of Dealer’s Licences Regulations, the fee for dealer’s licences: human drugs will increase by the annual 2% amount, rounded up to the nearest dollar. Under subsection 17(1) of the Service Fees Act (a fee is adjusted in each fiscal year — on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment — by the percentage change over 12 months in the April All-items Consumer Price Index [CPI] for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), the dealer’s licence: veterinary drugs [as per the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations] will be adjusted by the CPI. Health Canada has chosen April 1 as the anniversary date. The CPI for this year is 4.4%.
The current fees and the fees updated as of April 1, 2024, are listed below.
Any inquiries or comments about the updated fees can be directed to Shannon Laforce, Acting Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 343‑572‑4094 (telephone) or cro-brc@hc-sc.gc.ca (email).
| Type of licence | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|
| Dealer’s licence (human drugs) | $5,726 | $5,841 |
| Dealer’s licence (veterinary drugs) | $2,010.53 | $2,098.99 |
DEPARTMENT OF HEALTH
FOOD AND DRUGS ACT
Notice of annual adjustment of the Fees in Respect of Drugs and Medical Devices Order
Notice is hereby given, under subsection 30.61(1) of the Food and Drugs Act, that in keeping with section 4.1 of the 2020 Fees in Respect of Drugs and Medical Devices Order, every fee outlined in the Order is to be adjusted annually based on the Consumer Price Index (CPI). The CPI is calculated based on the percentage change over 12 months in the April All-items CPI for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year. The CPI for this year is 4.4%.
Most fees in the Fees in Respect of Drugs and Medical Devices Order are currently being phased in over four or seven years.
The current fees and the fees updated as of April 1, 2024, are listed below.
Any inquiries or comments about the updated fees can be directed to Shannon Laforce, Acting Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 343‑572‑4094 (telephone) or cro-brc@hc-sc.gc.ca (email).
Human Drug Submission Review
Part 2 — Drugs
| Section in the Fees in Respect of Drugs and Medical Devices Order | Submission class | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Section 9 | New active substance | $565,465 | $590,346 |
| Clinical or non-clinical data, and chemistry and manufacturing data | $292,806 | $305,690 | |
| Clinical or non-clinical data only | $117,080 | $122,232 | |
| Comparative studies | $65,985 | $68,889 | |
| Chemistry and manufacturing data only | $40,597 | $42,384 | |
| Clinical or non-clinical data only, in support of safety updates to the labelling | $21,429 | $22,372 | |
| Labelling only | $5,901 | $6,161 | |
| Labelling only (generic drugs) | $2,217 | $2,315 | |
| Administrative submission | $933 | $975 | |
| Disinfectant — full review | $12,297 | $12,839 | |
| Labelling only (disinfectants) | $2,764 | $2,886 | |
| Drug identification number application — labelling standard | $1,782 | $1,861 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of submission | Component | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|---|
| Section 21 | Application for drug identification number (DIN) | Information, other than that referred to in the item below, to support an application for a drug identification number, including the submission of labelling material for a second review, if required | $1,891 | $2,257 |
| Published references or other data | $1,314 | $1,569 | ||
| Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug | $658 | $786 | ||
| Notification — veterinary health product | Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product | $538 | $562 | |
| New drug submissions (NDS) | Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species) | $41,917 | $50,015 | |
| Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species | $25,392 | $30,298 | ||
| Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species | $60,961 | $72,735 | ||
| Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species | $82,548 | $98,491 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration | $7,610 | $9,079 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength | $1,261 | $1,505 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $57,158 | $68,199 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $76,201 | $90,918 | ||
| For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration | $7,610 | $9,079 | ||
| For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species | $38,088 | $45,446 | ||
| Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug | $12,697 | $15,150 | ||
| Chemistry and manufacturing data to support one strength of a single dosage form | $12,697 | $15,150 | ||
| Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the item above | $6,350 | $7,578 | ||
| Documentation to support a change of manufacturer | $658 | $786 | ||
| Supplement to a new drug submission (SNDS) | Efficacy data to support an additional indication in one animal species | $33,026 | $39,406 | |
| Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species | $25,392 | $30,298 | ||
| Efficacy and safety data (in the intended species) to support an indication in another animal species | $41,917 | $50,015 | ||
| Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species | $60,961 | $72,735 | ||
| Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species | $82,548 | $98,491 | ||
| Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species | $20,305 | $24,225 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration | $7,610 | $9,079 | ||
| Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength | $1,261 | $1,505 | ||
| For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species | $7,610 | 9,079 | ||
| For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species | $38,088 | $45,446 | ||
| For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period | $19,045 | $22,724 | ||
| For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required | $15,243 | $18,187 | ||
| Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process | $12,697 | $15,150 | ||
| Chemistry and manufacturing data to support a change in formulation or dosage form | $6,350 | $7,578 | ||
| Chemistry and manufacturing data to support a change in the packaging or sterilization process | $5,065 | $6,043 | ||
| Chemistry and manufacturing data to support an extension of the expiry date | $3,807 | $4,541 | ||
| Chemistry and manufacturing data to support the concurrent use of two drugs | $3,807 | $4,541 | ||
| Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form | $1,261 | $1,505 | ||
| Documentation to support a change to the brand name of a drug | $658 | $786 | ||
| Abbreviated new drug submission (ANDS) or supplement to an abbreviated new drug submission (SANDS) | Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form | $7,610 | $9,079 | |
| For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product | $7,610 | $9,079 | ||
| Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug | $12,697 | $15,150 | ||
| Chemistry and manufacturing data to support a single dosage form | $12,697 | $15,150 | ||
Documentation to support
|
$658 | $786 | ||
| Preclinical submission | Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species | $12,697 | $15,150 | |
| Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated | $10,153 | $12,114 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $38,088 | $45,446 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $57,158 | $68,199 | ||
| For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species | $76,201 | $90,918 | ||
| For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species | $19,045 | $22,724 | ||
| Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient | $12,697 | $15,150 | ||
| Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient | $6,350 | $7,578 | ||
| Sale of new drug for emergency treatment | Information and material to support the sale of a new drug to be used in the emergency treatment of a non-food-producing animal | $57 | $60 | |
| Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal | $114 | $120 | ||
| Experimental studies certificate | Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal | $1,082 | $1,130 | |
| Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a non-food-producing animal | $542 | $566 | ||
| Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal | $3,262 | $3,406 | ||
| Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal | $542 | $566 | ||
| Notifiable change or protocol review | Information and material to support an application for a notifiable change | $3,413 | $4,072 | |
| A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate | $3,413 | $4,072 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Activity | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Sections 33 and 41 | Fabrication — sterile dosage form | $46,221 | $48,225 |
| Sections 34 and 42 | Importation | $35,688 | $37,259 |
| Sections 35 and 43 | Fabrication — non-sterile dosage form | $34,266 | $35,774 |
| Sections 36 and 44 | Distribution | $18,251 | $19,017 |
| Sections 37 and 45 | Wholesaling | $10,630 | $11,098 |
| Sections 38 and 46 | Packaging/labelling | $6,681 | $6,975 |
| Sections 39 and 47 | Testing | $5,514 | $5,757 |
| Section 40 | Foreign site (each) | $1,014 | $1,059 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Activity | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Sections 33 and 41 | Fabrication — sterile dosage form | $45,262 | $47,588 |
| Sections 34 and 42 | Importation | $23,066 | $30,099 |
| Sections 35 and 43 | Fabrication — non-sterile dosage form | $18,905 | $24,641 |
| Sections 36 and 44 | Distribution | $10,409 | $13,583 |
| Sections 37 and 45 | Wholesaling | $4,161 | $5,431 |
| Sections 38 and 46 | Packaging/labelling | $6,681 | 6,975 |
| Sections 39 and 47 | Testing | $2,833 | 3,695 |
| Section 40 | Foreign site (each) | $1,014 | 1,059 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of drug | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Section 52 | Disinfectant | $1,613 | 1,684 |
| Non-prescription | $3,109 | 3,246 | |
| Drug other than one referred to in item 1 or 2 (above) | $5,158 | 5,385 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Type of drug | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Section 56 | Veterinary drug | $528 | $552 |
Part 3 — Medical devices
| Section in the Fees in Respect of Drugs and Medical Devices Order | Category | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Section 60 | Applications for Class II licence | $589 | $615 |
| Applications for Class II licence amendment | $302 | $316 | |
| Applications for Class III licence | $12,987 | $13,559 | |
| Applications for Class III licence (near patient) | $27,666 | $28,884 | |
| Applications for Class III licence amendment — changes in manufacturing | $4,098 | $4,279 | |
| Applications for Class III licence amendment — significant changes not related to manufacturing | $10,425 | $10,884 | |
| Applications for Class IV licence | $28,165 | $29,405 | |
| Applications for Class IV licence amendment — changes in manufacturing | $4,098 | $4,279 | |
| Applications for Class IV licence amendment — significant changes not related to manufacturing | $14,902 | $15,558 | |
| Applications for Class II, III or Class IV licence or licence amendment — private label medical device | $163 | $171 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Fee category | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Section 71 | Medical device | $5,060 | $5,283 |
| Section in the Fees in Respect of Drugs and Medical Devices Order | Fee category | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Section 77 | Medical device | $421 | $440 |
DEPARTMENT OF HEALTH
PATENT ACT
Notice of annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations
Notice is hereby given, that in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.
The current fee and the fee updated as of April 1, 2024, are listed below.
Any inquiries or comments about the updated fee can be directed to Shannon Laforce, Acting Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 343‑572‑4094 (telephone) or cro-brc@hc-sc.gc.ca (email).
| Type of certificate | Subsection in Certificate of Supplementary Protection Regulations | Fee as of April 1, 2023 | Fee as of April 1, 2024 |
|---|---|---|---|
| Certificate of Supplementary Protection | 9(1) | $10,152 | $10,356 |
PRIVY COUNCIL OFFICE
Appointment opportunities
We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.
We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.
The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.
Current opportunities
The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.
| Position | Organization | Closing date |
|---|---|---|
| Director | Asia-Pacific Foundation of Canada | |
| Director | Bank of Canada | |
| Chairperson | Business Development Bank of Canada | |
| Director | Canada Foundation for Innovation | |
| Director | Canada Foundation for Sustainable Development Technology | |
| Director | Canada Infrastructure Bank | |
| Chairperson | Canada Mortgage and Housing Corporation | |
| Director | Canada Mortgage and Housing Corporation | |
| President | Canada Mortgage and Housing Corporation | |
| Director | Canada Revenue Agency | |
| Chairperson | Canadian Accessibility Standards Development Organization | |
| Director | Canadian Accessibility Standards Development Organization | |
| Director | Canadian Centre on Substance Abuse | |
| Director | Canadian Commercial Corporation | |
| Chief Executive Officer | Canadian Energy Regulator | |
| Commissioner | Canadian Energy Regulator | |
| Director | Canadian Energy Regulator | |
| Chief Commissioner | Canadian Grain Commission | |
| Chief Commissioner | Canadian Human Rights Commission | |
| Member | Canadian Human Rights Tribunal | |
| Member | Canadian Institutes of Health Research | |
| President | Canadian Institutes of Health Research | |
| Member | Canadian International Trade Tribunal | |
| Chairperson | Canadian Museum for Human Rights | |
| President | Canadian Nuclear Safety Commission | |
| Member | Canadian Statistics Advisory Council | |
| Director | Canadian Tourism Commission | |
| Chairperson | Canadian Transportation Accident Investigation and Safety Board | |
| Member | Canadian Transportation Accident Investigation and Safety Board | |
| Member | Canadian Transportation Agency | |
| Member | Copyright Board | |
| Director | Export Development Canada | |
| Director | First Nations Financial Management Board | |
| Commissioner | First Nations Tax Commission | |
| Director (Federal) | Halifax Port Authority | |
| Member | Historic Sites and Monuments Board of Canada | |
| Clerk of the House of Commons | House of Commons | |
| Law Clerk and Parliamentary Counsel | House of Commons | |
| Member | Independent Advisory Board on Eligibility for Journalism Tax Measures | |
| Vice-Chairperson | Independent Advisory Board on Eligibility for Journalism Tax Measures | |
| Dispute/Appellate Panellist | Internal Trade Secretariat – Canadian Free Trade Agreement | |
| Commissioner | International Commission on the Conservation of Atlantic Tunas | |
| Commissioner | International Joint Commission | |
| Chairperson | Laurentian Pilotage Authority | |
| Chairperson | Military Grievances External Review Committee | |
| Vice-Chairperson | Military Grievances External Review Committee | |
| Chairperson | National Advisory Council on Poverty | |
| Member (Children’s Issues) | National Advisory Council on Poverty | |
| Commissioner | National Battlefields Commission | |
| Chairperson | National Seniors Council | |
| Member | National Seniors Council | |
| Canadian Representative | North Atlantic Salmon Conservation Organization | |
| Canadian Representative | North Pacific Anadromous Fish Commission | |
| Conflict of Interest and Ethics Commissioner | Office of the Conflict of Interest and Ethics Commissioner | |
| Director of Public Prosecutions | Office of the Director of Public Prosecutions | |
| President | Public Service Commission | |
| Principal | Royal Military College of Canada | |
| Clerk of the Senate and Clerk of the Parliaments | Senate | |
| Member | Social Sciences and Humanity Research Council | |
| Member | Standards Council of Canada | |
| Chairperson | Telefilm Canada | |
| Member | Telefilm Canada | |
| Member | Veterans Review and Appeal Board | |
| Director | VIA Rail Canada Inc. |